Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04095273 · ClinicalTrials.gov registry record · Phase 1
Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug
A Phase 1 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT04095273 is a Phase 1 study that has completed, run by Bayer. The registered enrollment target is 56 participants.
The verdict
NCT04095273, a Phase 1 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
The purpose of the study is to test how well patients with advanced solid tumors respond to treatment with elimusertib (BAY1895344) in combination with pembrolizumab. In addition researchers want to find for patients the optimal dose of elimusertib in combination with pembrolizumab, how the drug is tolerated and the way the body absorbs, distributes and discharges the drug. The study medication, elimusertib, works by blocking a substance (ATR Kinase) which is produced by the body and is important for the growth of tumor cells. Pembrolizumab is an immunologic checkpoint blocker that promotes an immune response against the tumor.
Interventions
- DRUG Elimusertib (BAY1895344)
- DRUG Pembrolizumab (Keytruda®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2019-09-30 |
| Est. Completion | 2023-04-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04095273
The ClinicalTrials.gov registry entry for NCT04095273 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Elimusertib (BAY1895344) is the first listed.
NCT04095273 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04095273 about?
NCT04095273 is a clinical study titled "Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug". The purpose of the study is to test how well patients with advanced solid tumors respond to treatment with elimusertib (BAY1895344) in combination with pembrolizumab. In addition researchers want to find for patients the optimal dose of elimusertib in combination with pembrolizumab, how the drug is ...
What is the current status of trial NCT04095273?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2019-09-30. Estimated completion is 2023-04-11.
What interventions are being tested in trial NCT04095273?
The interventions under investigation include: Elimusertib (BAY1895344) (DRUG), Pembrolizumab (Keytruda®) (DRUG).
Who is sponsoring clinical trial NCT04095273?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.